News & Events
Sunshine Heart on track for US trial following Pre-IDE Meeting with FDA
22 / 12 / 2006
Key points Sunshine Heart achieved a significant milestone with a successful FDA meeting. C-PulseTM was presented to the FDA by leading US and Australian clinicians FDA provided positive feedback for the C-PulseT product and clinical focus …
Peptech to use UK listing to drive growth strategy
20 / 11 / 2006
Australian biotechnology company Peptech Limited (ASX:PTD) ("Peptech" or the "Company") today announced in London it is preparing to list on AIM, a market regulated by the London Stock Exchange. Peptech's Chief Executive Officer Dr John Chiplin said that the listing…
Sunshine Heart Completes First Tranche of $20 million Institutional Capital Raising
14 / 11 / 2006
Sunshine Heart today advised that it has now received $13.8 million from investors. This represents the first tranche of the $20 million institutional Capital Raising approved by shareholders at the Extraordinary General Meeting held on 20 October 2006. Consequently the…
Portland Orthopaedics' $360K US hip orderPortland's third US order since August exceeds sales expectations
19 / 10 / 2006
Portland Orthopaedics Limited (ASX:PLD) has received its third order from US distributor Plus Orthopedics Inc with the new order requesting a further $360,000 of primary hip replacements for immediate delivery. This is Portland's second order for the M-COR primary hip. The…
Sunshine Heart Announces Research and Develoment Agreement with Allegheny-Singer Research
16 / 10 / 2006
Sunshine Heart, Inc. (ASX: SHC) today announced a research and development agreement with the Allegheny-Singer Research Institute (ASRI) in Pittsburgh, USA. Under this agreement Sunshine Heart will evaluate the feasibility of using Allegheny's unique muscle energy converter (MEC) to power…
KaloBios Pharmaceuticals Appoints David W. Pritchard asPresident and Chief Executive Officer
12 / 10 / 2006
KaloBios Pharmaceuticals Inc., a privately held biopharmaceutical company, today announced the appointment of David W. Pritchard as president and chief executive officer. Mr. Pritchard has over 25 years of experience in general management, business development and financial…
Portland Orthopaedics' M-COR primary hip implants commence in US FDA approval in July and first three centres come on line in the USA
25 / 09 / 2006
Portland Orthopaedics Limited (ASX:PLD) first set of M-COR primary hip replacements have been implanted in three separate centres across the USA over the last week. The first implants in 6 patients follow US FDA approval of Portland's M-COR primary hip series in July and…
Suprelorin12r Registered in Australia
25 / 09 / 2006
Peptech Animal Health Pty Limited (PAH), a wholly-owned subsidiary of Australian biotechnology company Peptech Limited (ASX:PTD), today announced it had received registration approval for its advanced canine contraceptive, Suprelorin12r. Suprelorin12r, the next generation of…
CogState Signs its First Agreement with Merck
21 / 09 / 2006
Key points: - CogState technology to be used for the first time by Merck in a clinical trial - CogState's contracted future revenue exceeds A$2.4m - Merck is a global pharmaceutical company CogState Ltd (ASX:CGS) announced today that it has signed its…
Momentum growing for Sunshine Heart clinical trial - fifth patient receives implant
11 / 09 / 2006
Key Points Monash Medical Centre implants first patient Five investigational sites actively screening for patients in Australia and New Zealand Five people implanted with the C-PulseTM heart assist device Sydney, Australia. 11…
Sunshine Heart announces A$20m institutional capital raising
06 / 09 / 2006
Significant investment from major institutional investors A$8m investment from specialist venture capital investor CM Capital A$8.5m follow-on investments from founding shareholders Key step in delivering on North American clinical trial strategy Third party…
Portland Orthopaedics' $1.58m hip and cup order for US market - Portland's first big order
30 / 08 / 2006
30 August 2006, Sydney, Australia: Portland Orthopaedics Limited (ASX:PLD) has received a further significant order from US distributor Plus Orthopedics Inc requesting $1.58 million of primary hip replacements and cups. Deliveries will begin in September 2006. This order is…
CogState Announces First Agreement with Lundbeck
23 / 08 / 2006
Key points: - CogState technology to be used for the first time by H. Lundbeck A/S in a clinical trial - H. Lundbeck A/S is a Danish pharmaceutical company specialising in Central Nervous System drug development CogState Ltd (ASX:CGS)…
CogState Divests Therapeutic Drug Development Portfolio
21 / 08 / 2006
Key points: - Out-license agreement signed in respect of pre-clinical AT4 program with milestone based payments and on-going royalty - CogState's other therapeutic program, NLT, has been returned to its licensor - No further costs will be incurred on therapeutic…
Perth patient receives revolutionary heart assist device
14 / 08 / 2006
Sunshine Heart's unique heart assist pump called C-PulseTM has been successfully implanted in a patient at Royal Perth Hospital in Western Australia. The C-PulseTM, developed by Australian company Sunshine Heart, improves the heart function of patients with…
$1.67 Million Grant To Develop Pain Drug
03 / 08 / 2006
Spinifex Pharmaceuticals Pty Limited has received a $1.67 million Commercial Ready Grant from the Australian Federal government to accelerate development of its lead drug candidate for the treatment of neuropathic pain. Neuropathic pain is caused by damage to the sensory…
Sunshine Heart granted ethics approval from Royal Perth Hospital Sydney, Australia
03 / 08 / 2006
Sunshine Heart, Inc. (ASX: SHC) announced today that it has received ethics approval to commence its C-PulseTM clinical trial program at Royal Perth Hospital in Western Australia. Royal Perth Hospital joins Auckland City Hospital in New Zealand, the Alfred Hospital and…
Portland Orthopaedics' First Hip Order from US Distributor
03 / 08 / 2006
Portland Orthopaedics Limited (ASX:PLD) has received its first order from new US distributor Plus Orthopedics Inc for $420,000 for Portland's DTC revision hip. The DTC Hip is used for difficult hip replacement cases typically where a patient suffers poor bone quality and…
Portland Orthopaedics Wins US FDA Approval to Market NewPrimary Hips
27 / 07 / 2006
First US sales order expected within weeks Portland Orthopaedics Limited (ASX:PLD) has been granted US Food and Drug Administration (FDA) approval to market the company's new M-COR primary hip in the US. The company will now ramp-up its manufacturing in preparation…
CogState Announces United States Patent Approval
25 / 07 / 2006
CogState is pleased to announce that it has received a Notice of Allowance from the Unites States Patent & Trade Mark Office for CogState's key technology platform, used in the computer based tests of cognition that form the basis of its business (patent application US 10/343,067). …
Sunshine Heart receives positive progress reports from Product Development Partners
10 / 07 / 2006
Sunshine Heart Company (ASX, SHC) today announced that it's US Product Partners have achieved significant milestones towards the supply of products in preparation for the start of a USbased clinical trial of the C-PulseTM mid-2007. The Plexus Corporation, a US NASDAQ-listed…
Sunshine Heart appoints leading US and Australian cardiologists toMedical Advisory Board
30 / 06 / 2006
Sunshine Heart, Inc. (ASX, SHC) today announced the strengthening of its Medical Advisory Board (MAB) with the addition of two distinguished cardiologists. Sunshine Heart's Medical Advisory Board includes eleven leading international Heart Failure cardiologists and cardiac surgeons. …